Drug Approval | October 27, 2022
USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
The CRL did not identify any outstanding scientific issues with the product.
The CRL did not identify any outstanding scientific issues with the product.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Silo enters into commercial evaluation license agreement for next generation liposomes
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Avacc 3 has significant advantages over existing whooping cough vaccines
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Subscribe To Our Newsletter & Stay Updated
